Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.

Abstract

BACKGROUND/AIM:

Osteosarcoma is a rare type of bone cancer that affects mostly children and adolescents. First-line chemotherapy for osteosarcoma has not been improved for many decades. Eribulin has been used to treat breast cancer and liposarcoma in the clinic.

MATERIALS AND METHODS:

A patient-derived orthotopic xenograft (PDOX) mouse model of osteosarcoma was established by tumor insertion within the tibia. This model more closely mimics osteosarcoma in clinical settings and was used to test the efficacy of eribulin. Tibia-insertion osteosarcoma PDOX mouse models were randomized into two groups: a control group (n=4) and an eribulin-treatment group (n=5). Mice were treated for fourteen days, four weeks after initial implantation. Tumor size and body weight were measured, and tumor histology was examined.

RESULTS:

Significant tumor growth inhibition (p=0.044) was observed in mice treated with eribulin compared to the control group. Histology demonstrated necrosis in the eribulin-treated tumors. There was no body-weight loss in the treated mice.

CONCLUSION:

Eribulin may be a clinically-effective, off-label chemotherapy for recalcitrant osteosarcoma that has failed first- and second-line therapy.

• Authors: Nathaniel F Wu, Jun Yamamoto, Yusuke Aoki, Michael Bouvet, Robert M Hoffman
• Journal: Anticancer research (Anticancer Res) Vol. 41 Issue 4 Pg. 1779-1784 (Apr 2021) ISSN: 1791-7530 [Electronic] Greece
• PMID: 33813382 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Furans
• Ketones
• eribulin

Topics

• Adolescent
• Animals
• Antineoplastic Agents (pharmacology)
• Bone Neoplasms (drug therapy, pathology)
• Furans (pharmacology)
• Humans
• Ketones (pharmacology)
• Male
• Mice, Nude
• Necrosis
• Osteosarcoma (drug therapy, pathology)
• Tibia (drug effects, pathology)
• Tumor Burden (drug effects)
• Xenograft Model Antitumor Assays
• Mice